How to buy Rallybio Corporation stock (Rallybio Corporation)

Rallybio Corporation is a biotechnology business based in the US. Rallybio Corporation shares (RLYB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.91 – a decrease of 3.8% over the previous week. Rallybio Corporation employs 43 staff and has a trailing 12-month revenue of around $598,000.

Our top picks for where to buy Rallybio stock

Buy Rallybio Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Rallybio Corporation stock price (NASDAQ: RLYB)

Use our graph to track the performance of RLYB stocks over time.

Rallybio Corporation shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.91
52-week range	$0.84 - $3.46
50-day moving average more info button	$1.04
200-day moving average more info button	$1.34
Wall St. target price	$8.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.57

Is it a good time to buy Rallybio Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rallybio Corporation price performance over time

Historical closes compared with the close of $0.92 from 2024-12-26

1 week (2024-12-20)	-3.16%
1 month (2024-11-27)	-16.36%
3 months (2024-09-27)	-16.74%
6 months (2024-06-28)	-31.34%

1 year (2023-12-28)	-63.20%
2 years (2022-12-28)	-83.54%
3 years (2021-12-28)	9.3
5 years (2019-12-24)	N/A

Rallybio Corporation financials

Revenue TTM	$598,000
Gross profit TTM	$0
Return on assets TTM	-38.54%
Return on equity TTM	-67.39%
Profit margin	0%
Book value	$1.93
Market Capitalization more info button	$35.6 million

TTM: trailing 12 months

Rallybio Corporation share dividends

We're not expecting Rallybio Corporation to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.33% forward annual dividend yield)

Rallybio Corporation share price volatility

Over the last 12 months, Rallybio Corporation's shares have ranged in value from as little as $0.841 up to $3.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rallybio Corporation's is -1.673. This would suggest that Rallybio Corporation's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Rallybio Corporation has bucked the trend.

To put Rallybio Corporation's beta into context you can compare it against those of similar companies.

• Moderna (MRNA.US): 1.69
• Gilead Sciences (GILD.US): 0.192
• Biogen (BIIB.US): -0.061

Rallybio Corporation overview

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. .

Frequently asked questions

What percentage of Rallybio Corporation is owned by insiders or institutions?
Currently 4.058% of Rallybio Corporation shares are held by insiders and 76.272% by institutions. How many people work for Rallybio Corporation?
Latest data suggests 43 work at Rallybio Corporation. When does the fiscal year end for Rallybio Corporation?
Rallybio Corporation's fiscal year ends in December. Where is Rallybio Corporation based?
Rallybio Corporation's address is: 234 Church Street, New Haven, CT, United States, 06510 What is Rallybio Corporation's ISIN number?
Rallybio Corporation's international securities identification number is: US75120L1008